Phase 2 Results of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences will present new efficacy data from a phase 2 study evaluating pitolisant in patients with Prader-Willi syndrome.

Related Keywords

Kumar Budur ,Drug Administration ,Harmony Biosciences Holdings Inc ,Meaningful Improvements ,Pooled Analysis ,Randomized Clinical Trials ,Presentation Date ,Board Number ,Safety Results ,Placebo Controlled Proof ,Signal Detection Study ,Prader Willi Syndrome ,